High therapeutic potential of positive allosteric modulation of α7 nAChRs in a rat model of traumatic brain injury: Proof-of-concept

Joshua W. Gatson, James W. Simpkins, Victor V. Uteshev

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

There are currently no clinically efficacious drug therapies to treat brain damage secondary to traumatic brain injury (TBI). In this proof-of-concept study, we used a controlled cortical impact model of TBI in young adult rats to explore a novel promising approach that utilizes PNU-120596, a previously reported highly selective Type-II positive allosteric modulator (α7-PAM) of α7 nicotinic acetylcholine receptors (nAChRs). α7-PAMs enhance and prolong α7 nAChR activation, but do not activate α7 nAChRs when administered without an agonist. The rational basis for the use of an α7-PAM as a post-TBI treatment is tripartite and arises from: (1) the intrinsic ability of brain injury to elevate extracellular levels of choline (a ubiquitous cell membrane-building material and a selective endogenous agonist of α7 nAChRs) due to the breakdown of cell membranes near the site and time of injury; (2) the ubiquitous expression of functional α7 nAChRs in neuronal and glial/immune brain cells; and (3) the potent neuroprotective and anti-inflammatory effects of α7 nAChR activation. Therefore, both neuroprotective and anti-inflammatory effects can be achieved post-TBI by targeting only a single player (i.e., the α7 nAChR) using α7-PAMs to enhance the activation of α7 nAChRs by injury-elevated extracellular choline. Our data support this hypothesis and demonstrate that subcutaneous administration of PNU-120596 post-TBI in young adult rats significantly reduces both brain cell damage and reactive gliosis. Therefore, our results introduce post-TBI systemic administration of α7-PAMs as a promising therapeutic intervention that could significantly restrict brain injury post-TBI and facilitate recovery of TBI patients.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalBrain Research Bulletin
Volume112
DOIs
StatePublished - Mar 1 2015

Fingerprint

Nicotinic Receptors
Therapeutics
Choline
Brain Injuries
Young Adult
Brain
Anti-Inflammatory Agents
Cell Membrane
Gliosis
Traumatic Brain Injury
Wounds and Injuries
Neuroglia
Drug Therapy

Keywords

  • Alpha7
  • Choline
  • Nicotinic
  • PNU-120596
  • PNU120596
  • Traumatic brain injury

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

High therapeutic potential of positive allosteric modulation of α7 nAChRs in a rat model of traumatic brain injury : Proof-of-concept. / Gatson, Joshua W.; Simpkins, James W.; Uteshev, Victor V.

In: Brain Research Bulletin, Vol. 112, 01.03.2015, p. 35-41.

Research output: Contribution to journalArticle

@article{13e1eca136a044fd99efdba73c2742a2,
title = "High therapeutic potential of positive allosteric modulation of α7 nAChRs in a rat model of traumatic brain injury: Proof-of-concept",
abstract = "There are currently no clinically efficacious drug therapies to treat brain damage secondary to traumatic brain injury (TBI). In this proof-of-concept study, we used a controlled cortical impact model of TBI in young adult rats to explore a novel promising approach that utilizes PNU-120596, a previously reported highly selective Type-II positive allosteric modulator (α7-PAM) of α7 nicotinic acetylcholine receptors (nAChRs). α7-PAMs enhance and prolong α7 nAChR activation, but do not activate α7 nAChRs when administered without an agonist. The rational basis for the use of an α7-PAM as a post-TBI treatment is tripartite and arises from: (1) the intrinsic ability of brain injury to elevate extracellular levels of choline (a ubiquitous cell membrane-building material and a selective endogenous agonist of α7 nAChRs) due to the breakdown of cell membranes near the site and time of injury; (2) the ubiquitous expression of functional α7 nAChRs in neuronal and glial/immune brain cells; and (3) the potent neuroprotective and anti-inflammatory effects of α7 nAChR activation. Therefore, both neuroprotective and anti-inflammatory effects can be achieved post-TBI by targeting only a single player (i.e., the α7 nAChR) using α7-PAMs to enhance the activation of α7 nAChRs by injury-elevated extracellular choline. Our data support this hypothesis and demonstrate that subcutaneous administration of PNU-120596 post-TBI in young adult rats significantly reduces both brain cell damage and reactive gliosis. Therefore, our results introduce post-TBI systemic administration of α7-PAMs as a promising therapeutic intervention that could significantly restrict brain injury post-TBI and facilitate recovery of TBI patients.",
keywords = "Alpha7, Choline, Nicotinic, PNU-120596, PNU120596, Traumatic brain injury",
author = "Gatson, {Joshua W.} and Simpkins, {James W.} and Uteshev, {Victor V.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.brainresbull.2015.01.008",
language = "English (US)",
volume = "112",
pages = "35--41",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - High therapeutic potential of positive allosteric modulation of α7 nAChRs in a rat model of traumatic brain injury

T2 - Proof-of-concept

AU - Gatson, Joshua W.

AU - Simpkins, James W.

AU - Uteshev, Victor V.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - There are currently no clinically efficacious drug therapies to treat brain damage secondary to traumatic brain injury (TBI). In this proof-of-concept study, we used a controlled cortical impact model of TBI in young adult rats to explore a novel promising approach that utilizes PNU-120596, a previously reported highly selective Type-II positive allosteric modulator (α7-PAM) of α7 nicotinic acetylcholine receptors (nAChRs). α7-PAMs enhance and prolong α7 nAChR activation, but do not activate α7 nAChRs when administered without an agonist. The rational basis for the use of an α7-PAM as a post-TBI treatment is tripartite and arises from: (1) the intrinsic ability of brain injury to elevate extracellular levels of choline (a ubiquitous cell membrane-building material and a selective endogenous agonist of α7 nAChRs) due to the breakdown of cell membranes near the site and time of injury; (2) the ubiquitous expression of functional α7 nAChRs in neuronal and glial/immune brain cells; and (3) the potent neuroprotective and anti-inflammatory effects of α7 nAChR activation. Therefore, both neuroprotective and anti-inflammatory effects can be achieved post-TBI by targeting only a single player (i.e., the α7 nAChR) using α7-PAMs to enhance the activation of α7 nAChRs by injury-elevated extracellular choline. Our data support this hypothesis and demonstrate that subcutaneous administration of PNU-120596 post-TBI in young adult rats significantly reduces both brain cell damage and reactive gliosis. Therefore, our results introduce post-TBI systemic administration of α7-PAMs as a promising therapeutic intervention that could significantly restrict brain injury post-TBI and facilitate recovery of TBI patients.

AB - There are currently no clinically efficacious drug therapies to treat brain damage secondary to traumatic brain injury (TBI). In this proof-of-concept study, we used a controlled cortical impact model of TBI in young adult rats to explore a novel promising approach that utilizes PNU-120596, a previously reported highly selective Type-II positive allosteric modulator (α7-PAM) of α7 nicotinic acetylcholine receptors (nAChRs). α7-PAMs enhance and prolong α7 nAChR activation, but do not activate α7 nAChRs when administered without an agonist. The rational basis for the use of an α7-PAM as a post-TBI treatment is tripartite and arises from: (1) the intrinsic ability of brain injury to elevate extracellular levels of choline (a ubiquitous cell membrane-building material and a selective endogenous agonist of α7 nAChRs) due to the breakdown of cell membranes near the site and time of injury; (2) the ubiquitous expression of functional α7 nAChRs in neuronal and glial/immune brain cells; and (3) the potent neuroprotective and anti-inflammatory effects of α7 nAChR activation. Therefore, both neuroprotective and anti-inflammatory effects can be achieved post-TBI by targeting only a single player (i.e., the α7 nAChR) using α7-PAMs to enhance the activation of α7 nAChRs by injury-elevated extracellular choline. Our data support this hypothesis and demonstrate that subcutaneous administration of PNU-120596 post-TBI in young adult rats significantly reduces both brain cell damage and reactive gliosis. Therefore, our results introduce post-TBI systemic administration of α7-PAMs as a promising therapeutic intervention that could significantly restrict brain injury post-TBI and facilitate recovery of TBI patients.

KW - Alpha7

KW - Choline

KW - Nicotinic

KW - PNU-120596

KW - PNU120596

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84922613651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922613651&partnerID=8YFLogxK

U2 - 10.1016/j.brainresbull.2015.01.008

DO - 10.1016/j.brainresbull.2015.01.008

M3 - Article

C2 - 25647232

AN - SCOPUS:84922613651

VL - 112

SP - 35

EP - 41

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

ER -